Form4insider filings, from the source

SEC Form 4 · accession 0001209191-17-064701

AGIOS PHARMACEUTICALS, INC. · AGIO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Scott Biller
Officer — Chief Scientific Officer
Period of report
Dec 6, 2017
Accepted (ET)
Dec 8, 2017 · 4:22 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common stockDec 6, 2017M14,875$0.4675A21,139D
Common stockDec 6, 2017M102$0.4675A21,241D
Common stockDec 6, 2017M31,818$2.3375A53,059D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock option (right to buy)F1$0.4675Dec 6, 2017M14,875A—Dec 6, 2020Common stock14,8750D
Stock option (right to buy)F2$0.4675Dec 6, 2017M102A—Dec 6, 2020Common stock1024,867D
Stock option (right to buy)F3$2.3375Dec 6, 2017M31,818A—Apr 5, 2022Common stock31,81831,818D

Explanation of responses